

RESEARCH

Open Access



Days alive and out of hospital for adult female and male cardiac surgery patients: a population-based cohort study

Angela Jerath^{1,2,3,4*}, Christopher J. D. Wallis^{5,6,7}, Stephen Fremes^{4,8,11}, Vivek Rao^{9,10,11}, Terrence M. Yau^{10,11}, Kiyam Heybati¹², Douglas S. Lee^{3,10,13}, Harindra C. Wijeyesundera^{3,4}, Jason Sutherland¹⁴, Peter C. Austin³, Duminda N. Wijeyesundera^{3,15} and Dennis T. Ko^{3,4}

Abstract

Background Research shows women experience higher mortality than men after cardiac surgery but information on sex-differences during postoperative recovery is limited. Days alive and out of hospital (DAH) combines death, readmission and length of stay, and may better quantify sex-differences during recovery. This main objective is to evaluate (i) how DAH at 30-days varies between sex and surgical procedure, (ii) DAH responsiveness to patient and surgical complexity, and (iii) longer-term prognostic value of DAH.

Methods We evaluated 111,430 patients (26% female) who underwent one of three types of cardiac surgery (isolated coronary artery bypass [CABG], isolated non-CABG, combination procedures) between 2009 – 2019. Primary outcome was DAH at 30 days (DAH₃₀), secondary outcomes were DAH at 90 days (DAH₉₀) and 180 days (DAH₁₈₀). Data were stratified by sex and surgical group. Unadjusted and risk-adjusted analyses were conducted to determine the association of DAH with patient-, surgery-, and hospital-level characteristics. Patients were divided into two groups (below and above the 10th percentile) based on the number of days at DAH₃₀. Proportion of patients below the 10th percentile at DAH₃₀ that remained in this group at DAH₉₀ and DAH₁₈₀ were determined.

Results DAH₃₀ were lower for women compared to men (22 vs. 23 days), and seen across all surgical groups (isolated CABG 23 vs. 24, isolated non-CABG 22 vs. 23, combined surgeries 19 vs. 21 days). Clinical risk factors including multimorbidity, socioeconomic status and surgical complexity were associated with lower DAH₃₀ values, but women showed lower values of DAH₃₀ compared to men for many factors. Among patients in the lowest 10th percentile at DAH₃₀, 80% of both females and males remained in the lowest 10th percentile at 90 days, while 72% of females and 76% males remained in that percentile at 180 days.

Conclusion DAH is a responsive outcome to differences in patient and surgical risk factors. Further research is needed to identify new care pathways to reduce disparities in outcomes between male and female patients.

Keywords Days at home, Cardiac surgery, Sex, Epidemiology, Outcomes, Validation

*Correspondence:

Angela Jerath

Angela.Jerath@mail.utoronto.ca

Full list of author information is available at the end of the article



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Sex-differences in outcomes after cardiac surgery have been identified in early studies with poorer recovery demonstrated in women compared to men [1–3]. Overall mortality after cardiac surgery remains low (1–4%) [4] but this endpoint fails to capture the high incidence (16–35%) [5–7] of new morbidity after surgery that slows patient recovery. Further study of outcomes after cardiac surgery and how this differs between women and men is essential with more elderly multimorbid patients undergoing high risk procedures in contemporary practice that places them at elevated risk of new complications after surgery [8]. A composite outcome called failure to achieve an uneventful recovery that is based on complications has identified specific perioperative risk factors including female sex that are associated with higher risk of postoperative adverse events [9, 10]. Days alive and out of hospital (DAH) is a novel outcome that has been validated and used in non-cardiac surgery to capture global outcomes of the patient experience [11, 12]. DAH is a composite endpoint that integrates death, duration of hospitalization and long-term care, and can be measured over any time period. Non-cardiac surgery studies have shown this metric is appropriately responsive to the patients' preoperative health status and new problems that arise from the surgical experience. In addition, noncardiac surgery studies indicate that early assessment of DAH (i.e., within 30-days after surgery) has useful prognostic qualities for understanding the longer-term trajectory of patients' recovery [11]. DAH has become increasingly used as a global metric of patient outcomes for cardiology trials [13, 14], recommended measurement endpoint for perioperative studies, and used to evaluate trends in cardiac disease and policy implications [15–17].

DAH has not been evaluated in cardiac surgery, nor has the effect of patient sex or type of surgery on DAH. This knowledge gap forms the basis of this population cohort study which has 3 objectives. First, to determine how DAH varies between patient sex and cardiac surgical procedure. Second, to evaluate the construct validity of DAH based on its association with patient (e.g., sex), surgical (e.g., type) and hospital factors. Third, to determine if the early DAH value has longer-term prognostic value in female and male cardiac surgical patients.

Methods

Settings and data sources

This study is reported according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines and the Reporting of Studies Conducted Using Observational Routinely Collected Health Data (RECORD) statement. We conducted a

retrospective cohort study using population-based administrative healthcare databases in Ontario, Canada. The use of data in this project was authorized under Sect. 45 of Ontario's Personal Health Information Protection Act, which does not require review by a research ethics board. We used CorHealth Ontario to identify cardiac surgeries and specific cardiac health information. The Registered Persons Database (RPDB), Vital Statistics and Ontario census data were used to extract demographics, socioeconomic status and mortality. The Canadian Institute of Health Information Discharge Abstract Database (CIHI-DAD) captures all acute care hospital admissions and provided information additional information during primary hospitalization, and any readmissions. We used the Ontario Health Insurance Plan (OHIP) database to capture all physician service claim data. The Continuing Care Reporting System (CCRS) database was used to capture patients needing long-term care support. Specialized databases (Ontario Diabetes Database, Asthma Database, Chronic Obstructive Pulmonary Disease Database, Ontario Hypertension Database) were used to identify specific comorbidities. Laboratory values were obtained from the Ontario Laboratory Information System (OLIS). Data were linked through unique anonymized patient identifier numbers. Key variables and codes used are summarized in Supplemental Digital Content Tables S1 [11, 18, 19].

Study cohort

We identified adults (≥ 18 years) patients who underwent common elective and emergency cardiac surgeries between 2009 – 2019 in Ontario hospitals. The procedures included coronary bypass surgery (CABG), aneurysmectomy, valve repair/replacement, and aortic surgery. We excluded less commonly performed surgeries such as adult congenital heart procedures, heart transplantation and ventricular assist device implantation. The surgical procedures were placed into 3 clinically sensible groups based on operative complexity and commonly described description: (i) isolated CABG, (ii) single non-CABG procedures (e.g., single valve repair/replacement), and (iii) combined (2 or more) procedures (e.g., valve and CABG surgery, multiple valve surgery, aortic and CABG/valve surgery) [5, 7]. We excluded intraoperative deaths ($n=219$) in order to assess DAH in the postoperative period, patients with missing unique identifier number or death date ($n=75$), patient procedure dates and institution identified in DAD but not verified in CorHealth data ($n=5,350$). For patients with multiple surgeries during the study period, we excluded all but the first procedure ($n=5,673$).

Outcome

The primary outcome was DAH at 30 days after surgery (referred to as DAH₃₀). This was calculated using mortality, hospital length of stay, and readmissions between the date of the index surgery and the 30th postoperative day using validated sources from CIHI-DAD (supplemental figure S1) [20]. The approach to calculating DAH has been previously described. In brief, the duration a patient stays in hospital is subtracted from the measured time frame, for example, a patient who survived and was discharged 20 days after the indexed surgery had a DAH₃₀ of 10 days. Patients who died at any time during this 30-day period were assigned a DAH₃₀ of 0 days. The secondary outcomes were DAH at 90 days (DAH₉₀) and 180 days (DAH₁₈₀), which were determined using similar calculations.

Covariates

Demographics (age, sex) were identified from the RPDB. Comorbidities (coronary artery disease, diabetes, hypertension, chronic obstructive pulmonary disease, atrial fibrillation, asthma, body mass index, stroke, chronic liver disease, smoking status, anemia, left ventricular ejection fraction, components of the Charlson comorbidity index score) were extracted from CorHealth, OLIS, CIHI-DAD (using ICD-10 codes from hospital admissions) and specialized validated Ontario databases within 3 years before the index surgery [21–24]. Severity of preoperative kidney dysfunction was classified into one of 5 stages of KDIGO renal function based on the patient's estimated glomerular function prior to surgery [25]. To capture level of patient acuity and sickness before surgery, we recorded those patients needing preoperative intensive level care and DAH in the 3 months preceding the day of indexed surgery. Frailty was estimated using the hospital frailty risk score [26]. Socioeconomic status was based on neighborhood income quintile (1 is lowest, 5 is highest) and extracted from StatsCan. Major (grade 3–4 Clavien-Dindo) complications within 30-days after surgery needing ICU readmission, reoperation, rehospitalization, or another advanced intervention (e.g., pacemaker, angioplasty, dialysis, tracheostomy, prolonged ventilation, prolonged ICU admission, balloon pump, endoscopic procedure, extra-corporeal support) were extracted from CorHealth, CIHI-DAD, OLIS and OHIP [27–29]. Surgery variables include procedure type, duration, and urgency. Hospital variables included surgical volume, teaching status and bed number [20].

Statistical analysis

Descriptive statistics were used to initially compare male and female patients using frequency (proportion)

for categorical variables, median (interquartile range, IQR) for continuous variables and standardized difference. Subsequently, men and women were studied and reported separately. For each sex-group, descriptive statistics were estimated for each of the three surgical groups (single CABG, single non-CABG, combined surgeries). Construct validity describes how DAH responds to patient and surgical risk factors. We expect DAH to show convergent validity with lower DAH values in patients undergoing more complex procedures or display higher burden of chronic diseases. Hence, to evaluate construct validity of patient level factors and type of surgery, and how this differs for female and male patients, we summarized the unadjusted effect of common patient comorbidities (e.g., diabetes, atrial fibrillation, stroke, body mass index, chronic obstructive pulmonary disease, chronic kidney and liver disease, smoking status, socioeconomic status, and surgery type) on DAH at 30-days using median (IQR). To study the adjusted association of patient, surgery and hospital factors with DAH, we used a multivariable median regression model to model the association of covariates (with the median DAH [30]). This approach has been previously used to manage the skewed nature of our data [9, 16]. The model incorporated hospital-specific random effects to account for within-hospital clustering. Separate models were developed for male and female patients for DAH at 30, 90 and 180 days using the above covariates. A sensitivity analysis was performed after removal of complications from the model. To formally evaluate whether there was an interaction between patient sex and modifiable risk factors (e.g., hospital teaching status, procedure group), we fit the above model to the entire sample of men and women combined and included an interaction term between patient sex and the given risk factor. This was done sequentially for one risk factor at a time. Risk adjusted models were performed on a cohort of 87,826 patients during the study time frame after removal of missing variables (rural 0.1%, income quintile 0.3%, surgery duration 0.2%, left ventricular function 3%, body mass index 5%, smoking status 2%, kidney function 14%). No imputation of data was performed.

We explored the prognostic implications of our sickest patients with the fewest number of DAH at 30 days. After removing patients who died during this 30-day period, patients were ranked based on their value of DAH at 30 days, and then placed into 2 groups—those in the lowest 10th percentile and those above this percentile. The 10th percentile cut-off has been previously used for non-cardiac surgery to capture those patients with the poorest number of DAH, and is appropriate given the left skewness of the data distribution [11]. Patient, surgical and hospital characteristics of those below and above

the 10th percentile were quantified using median (IQR), frequency (percentage) and standardized differences. We subsequently determined the proportion of patients in below and above the 10th percentile at 30 days that remained within these group at 90 and 180 days.

The trajectory and morbidity of individual cardiac surgeries subtly vary. For example, in the single non-CABG group, outcomes may be different for men and women undergoing mitral valve versus tricuspid valve surgery. To further explore this, we performed pre-specified sub-group analyses within the isolated non-CABG and combined procedure surgical groups to study these differences in operations between patient sex. This was performed using the same above risk adjusted model for the outcomes of DAH at 30 days.

All analyses were conducted using Microsoft Excel (v.2010, Redmond, WA), SAS version 9.4 (SAS Institute, Cary, US) and R statistical software [31–33]. Two-sided p -values < 0.05 were considered statistically significant. No statistical power calculation was performed prior to conducting this study and the sample size was based on the available data meeting the above eligibility requirements. This sample was based on our previous experience in conducting health services research using this patient population and research design [19, 34].

Results

The cohort included 111,430 patients with 28,437 (26%) women and 82,993 (74%) men. The majority (63%) of procedures were isolated CABG, followed by combined (21%) and single non-CABG (16%) surgeries (Table 1). Overall, patients undergoing combined surgeries were older with more chronic medical diseases compared to isolated CABG or isolated non-CABG surgery with fewer DAH at all time points compared to isolated CABG and non-CABG surgery.

Compared to male patients, female patients were more advanced in age (69y vs. 66y), showed greater burden of comorbidities, a higher proportion of lower socioeconomic status (income quintile 1/2, 43% vs. 37%) and underwent more complex combined surgeries (25% vs. 19%), Table 1. The median DAH₃₀ for men and women was 23 and women 22 days respectively ($p < 0.001$), Table 1. Among male patients, DAH₃₀ for isolated CABG, isolated non-CABG and combined surgery were 24, 23 and 21 days respectively, Supplemental Table S2. Number of days at DAH₃₀ in women undergoing for isolated CABG, isolated non-CABG and combined surgery were lower than men at 23, 22 and 19 days respectively. Similar trends with fewer DAH among women were sustained at 90 and 180 days, Supplemental Table S2.

The unadjusted association of patient factors with DAH is summarized in Table 2. Presence of common

comorbidities were associated with a greater reduction in median DAH₃₀ among women compared to men for e.g., Charlson Comorbidity Index ≥ 2 : 19 vs. 22 days, grade 5 kidney disease: 13 vs. 17 days. The number of DAH₃₀ fell in patients of lower socioeconomic status. For each income quintile group women showed fewer DAH compared to men (median DAH₃₀ income quintile 1 to 5, 21–22 [female] vs. 23–24 [male]).

Risk adjusted multivariable models were conducted on 87,826 patients, 22,573 (26%) women and 65,253 (74%) men, after removal of those with missing data. Patient characteristics such as age, chronic health problems (e.g., atrial fibrillation, diabetes, chronic kidney disease, cerebro- and peripheral vascular disease, frailty), lower income quintile were all associated with reduction in DAH₃₀ (Fig. 1). However, there was a greater magnitude in reduction for most covariates among female patients compared to males. Complexity of surgery showed appropriate changes in DAH₃₀ with greatest reduction in combined procedures followed by isolated non-CABG surgery compared to CABG. However, within each surgical group, females fared worse than males. Incurring a postoperative complication showed significant reductions in DAH₃₀ by 2.8 days (95% CI -3.8 to -1.9) in females and 2.2 days in males (95% CI -3.0 to -1.4). Acuity and duration of surgery was important with urgent/emergency procedures and longer surgeries showing lower DAH₃₀. Hospital factors such as size and teaching status were not associated with DAH₃₀. Similar trends were seen at DAH₉₀ and DAH₁₈₀ (Supplemental Fig. S2). Sensitivity analyses after removal of patients experiencing a peri-operative complications showed similar findings (Supplemental Table S3). There was a significant interaction between patient sex and isolated non-CABG surgery (Supplemental Table S4).

After removing deaths within 30-days after surgery ($n = 847$), patients residing below the 10th percentile were undergoing more combined surgeries at an advanced age with greater comorbidity burden compared to those above the 10th percentile (Supplemental Table S5). Male and female patients below the 10th percentile showed many similar perioperative characteristics except some comorbidities (e.g., anemia, asthma, frailty) which were more common in women. Patients in the > 10 th percentile group at 30-days continued to recover well with 98% and 97% remaining in this group at 90- and 180-days respectively for both female and male patients (Table 3). The proportion of patients in the < 10 th group at 30-days who remained in this group at 90- and 180-days were respectively 80% and 72% for females, and 80% and 76% for males.

Among patients in the isolated non-CABG surgery, most patients underwent single aortic valve surgery,

Table 1 Descriptive characteristics of cardiac surgery patients stratified by sex and surgical group

	Female N= 28,437	Male N= 82,993	Total N= 111,430	Standardized Difference
Patient factors				
Age	69 (61–76)	66 (59–74)	67 (59–74)	0.24
Atrial fibrillation	4,157 (14.6%)	8,934 (10.8%)	13,091 (11.7%)	0.12
Anemia	2,999 (10.5%)	4,806 (5.8%)	7,805 (7.0%)	0.17
Asthma	5,323 (18.7%)	8,770 (10.6%)	14,093 (12.6%)	0.23
CAD	14,351 (50.5%)	46,061 (55.5%)	60,412 (54.2%)	0.1
Stroke	806 (2.8%)	2,090 (2.5%)	2,896 (2.6%)	0.02
Dementia	83 (0.3%)	181 (0.2%)	264 (0.2%)	0.01
Diabetes	12,391 (43.6%)	34,881 (42.0%)	47,272 (42.4%)	0.03
Dialysis	475 (1.7%)	1,299 (1.6%)	1,774 (1.6%)	0.01
Hypertension	23,961 (84.3%)	68,458 (82.5%)	92,419 (82.9%)	0.05
Chronic liver disease	216 (0.8%)	617 (0.7%)	833 (0.7%)	0
Myocardial infarction	7,147 (25.1%)	23,326 (28.1%)	30,473 (27.3%)	0.07
PVD	1,858 (6.5%)	5,253 (6.3%)	7,111 (6.4%)	0.01
Primary cancer	661 (2.3%)	2,118 (2.6%)	2,779 (2.5%)	0.01
Secondary cancer	109 (0.4%)	246 (0.3%)	355 (0.3%)	0.01
COPD	3,456 (12.2%)	8,168 (9.8%)	11,624 (10.4%)	0.07
^b Chronic kidney disease				
Stage 1	6,149 (21.6%)	22,947 (27.6%)	29,096 (26.1%)	0.14
Stage 2	10,947 (38.5%)	32,419 (39.1%)	43,366 (38.9%)	0.01
Stage 3	6,249 (22.0%)	13,286 (16.0%)	19,535 (17.5%)	0.15
Stage 4	1,035 (3.6%)	1,991 (2.4%)	3,026 (2.7%)	0.07
Stage 5	344 (1.2%)	903 (1.1%)	1,247 (1.1%)	0.01
CCI ≥ 2	9,027 (31.7%)	23,775 (28.6%)	32,802 (29.4%)	0.07
Rural	4,237 (14.9%)	12,539 (15.1%)	16,776 (15.1%)	0.01
Income quintile				
Q1	6,284 (22.2%)	14,752 (17.8%)	21,036 (18.9%)	0.11
Q2	6,052 (21.4%)	16,582 (20.0%)	22,634 (20.4%)	0.03
Q3	5,677 (20.0%)	17,057 (20.6%)	22,734 (20.5%)	0.01
Q4	5,268 (18.6%)	17,156 (20.7%)	22,424 (20.2%)	0.05
Q5	5,055 (17.8%)	17,162 (20.7%)	22,217 (20.0%)	0.07
Body mass index				
≤ 25	8,206 (28.9%)	19,187 (23.1%)	27,393 (24.6%)	0.13
26–30	8,574 (30.2%)	32,880 (39.6%)	41,454 (37.2%)	0.2
≥ 31	10,274 (36.1%)	26,736 (32.2%)	37,010 (33.2%)	0.08
LVEF				
< 20%	241 (0.8%)	1,509 (1.8%)	1,750 (1.6%)	0.08
20%–34%	1,715 (6.0%)	7,190 (8.7%)	8,905 (8.0%)	0.1
35%–49%	4,378 (15.4%)	17,549 (21.1%)	21,927 (19.7%)	0.15
≥ 50%	21,233 (74.7%)	54,069 (65.1%)	75,302 (67.6%)	0.21
Smoking status				
Current	4,523 (16.1%)	16,682 (20.3%)	21,205 (19.2%)	0.11
Former	6,799 (24.1%)	31,231 (38.0%)	38,030 (34.5%)	0.3
Never	16,554 (58.8%)	33,472 (40.7%)	50,026 (45.3%)	0.37
Frailty	2 (0–5)	1 (0–3)	1 (0–4)	0.19
Preop DAH (3m—1d)	89 (82–92)	89 (83–92)	89 (83–92)	0.04
Surgery				
Surgery duration (min)	268 (223–323)	273 (230–326)	271 (228–325)	0.07
Re-do surgery	833 (5.5%)	1,835 (4.4%)	2,668 (4.7%)	0.05

Table 1 (continued)

	Female N = 28,437	Male N = 82,993	Total N = 111,430	Standardized Difference
Preop ICU level care	15,913 (56%)	47,358 (57.1%)	63,271 (56.8%)	0.02
Elective	17,975 (63.2%)	51,316 (61.8%)	69,291 (62.2%)	0.03
Urgent/Emergent	10,462 (36.8%)	31,677 (38.2%)	42,139 (37.8%)	0.03
Surgical group				
Combined surgeries	7,393 (26.0%)	16,352 (19.7%)	23,745 (21.3%)	0.15
Isolated non-CABG procedure	6,933 (24.4%)	10,298 (12.4%)	17,231 (15.5%)	0.31
Isolated CABG	14,111 (49.6%)	56,343 (67.9%)	70,454 (63.2%)	0.38
Hospital				
Teaching hospital	17,634 (62.0%)	50,531 (60.9%)	68,165 (61.2%)	0.02
ICU Beds	61 (35–77)	60 (35–74)	60 (35–74)	0.03
Surgical Beds	131 (84–210)	131 (84–176)	131 (84–176)	0.01
Total Beds	367 (288–514)	367 (291–513)	367 (291–513)	0
Outcomes				
30-day mortality	418 (1.5%)	778 (0.9%)	1,196 (1.1%)	0.05
90-day mortality	670 (2.4%)	1,238 (1.5%)	1,908 (1.7%)	0.06
ICU LOS (h)	47 (25–95)	37 (23–75)	42 (24–78)	0.17
ALC patient	1,380 (4.9%)	2,155 (2.6%)	3,535 (3.2%)	0.12
Postop LOS (d)	7 (6–10)	6 (5–8)	6 (5–9)	0.38
Major complications	6,148 (21.6%)	14,132 (17.0%)	20,280 (18.2%)	0.12
30-day hospital readmission	3840 (13.5%)	8293 (10.0%)	12,133 (10.9%)	0.11
90-day hospital readmission	5681 (20%)	12,357 (14.9%)	18,038 (16.2%)	0.13
180-day hospital readmission	6998 (24.6%)	15,697 (18.9%)	22,695 (20.4%)	0.14
^a DAH ₃₀	22 (16–24)	23 (20–25)	23 (19–25)	0.42
	18.5 ± 7.8	20.8 ± 6.7	20.2 ± 7.1	0.31
^a DAH ₉₀	81 (74–84)	83 (79–85)	83 (78–85)	0.42
	73.0 ± 20.7	77.5 ± 16.8	76.3 ± 18.0	0.24
^a DAH ₁₈₀	171 (162–173)	173 (168–175)	172 (166–174)	0.41
	156.5 ± 39.8	163.4 ± 32.0	161.6 ± 34.2	0.19

ALC alternate care; CAD coronary artery disease; CCI Charlson comorbidity index; COPD chronic obstructive pulmonary disease; d days; DAH days alive and out of hospital; h hours; ICU intensive care unit; LOS length of stay; LVEF left ventricular ejection fraction; m month; PVD peripheral vascular disease

^a DAH described using median (inter-quartile range) and mean ± standard deviation

^b Chronic kidney disease divided into 5 groups using Kidney Disease Improving Global Outcomes (KDIGO) classification based on preoperative estimated glomerular filtration rate

followed by mitral valve, tricuspid/pulmonic valve and aneurysctomy or aortic surgery with median DAH₃₀ varying between 18–22 days for females and 22–23 days for males. Within combined procedures, most patient underwent CABG and valve surgery, multi-valve surgery or valve with aortic surgery with DAH₃₀ varying 16–22 days for females and 19–23 days for males (Supplemental Table S6). In the isolated non-CABG surgery group, there was no significant difference between procedures on DAH₃₀ after risk adjustment for both males and females (Supplemental Table S7). In the combined procedure group, females undergoing triple procedures showed the greatest reduction in DAH₃₀ (-1.4, 95% CI -2.0 to -0.8 days) with similar but smaller finding in male patients (-0.8, 95% CI -1.3 to -0.3).

Discussion

This observational study shows DAH is a useful instrument for evaluating the impact of surgery with appropriate and responsive change to patient comorbidities, social and economic status, surgical complexity and new complications that impact patient recovery. Similar to validation studies in noncardiac surgery, DAH is unaffected by hospital factors such as bed number and teaching status [11]. This study also shows that early outcomes at 30-days are indicative of longer-term recovery.

This study highlights sex-based disparities in patient outcomes and the importance of separate reporting of male and female adult patients in cardiac surgery. Early studies revealed differences between male and female patient outcomes in cardiovascular disease [1–3]. This

Table 2 Unadjusted changes in days alive and out of hospital at 30- and 90-days for patient factors stratified by patient sex

	DAH ₃₀			
	Female		Male	
	Median	IQR	Median	IQR
Patient factors				
CCI ≥ 2	19	10–23	22	16–24
COPD	19	11–23	21	14–24
Diabetes	21	15–24	23	19–25
Peripheral vascular disease	20	12–23	22	16–24
Atrial fibrillation	18	9–22	20	13–23
Stroke/TIA	18	7–23	21	13–24
Chronic liver disease	13	0–21	18	6–23
Chronic kidney disease				
Stage 1	23	21–25	24	22–25
Stage 2	22	18–24	23	21–25
Stage 3	19	11–23	21	15–24
Stage 4	13	0–20	16	1–22
Stage 5	13	0–20	17	3–22
Income Quintile				
Q1	21	14–24	23	19–25
Q2	22	16–24	23	20–25
Q3	22	16–24	24	20–25
Q4	22	16–24	24	20–25
Q5	22	17–24	24	21–25
Smoking Status				
Current	22	16–24	24	20–25
Ex-smoker	22	16–24	23	20–25
Never smoked	22	16–24	23	20–25
Left ventricular ejection fraction				
< 20%	19	4–23	20	10–24
20%–34%	19	9–23	22	16–24
35%–49%	21	14–24	23	19–25
≥ 50%	22	17–24	24	21–25
Preoperative ICU	22	16–24	23	20–25
BMI				
≤ 25	22	16–24	23	19–25
26–30	22	17–24	24	21–25
≥ 31	22	16–24	23	20–25
Surgeries				
Isolated CABG	23	18–24	24	21–25
Single non-CABG				
Aortic valve	22	18–24	23	19–25
Mitral valve	22	17–24	23	20–25
Pulmonic/tricuspid	20	4–23	21	13–24
Aneurysectomy/aortic	16	4–21	21	14–24
Combined Surgeries				
CABG/valve ± other	19	10–23	21	15–24
Double valve	19	11–22	20	13–23
≥ 3 procedures ^a	16	2–21	19	9–22
Other ^b	21	15–24	23	17–24

Table 2 (continued)

^a ≥ 3 procedures includes triple valve, quadruple valve, double valve with aortic, CABG or aneurysectomy surgery

^b Other includes few combined surgeries of aortic and aneurysectomy, valve and aortic or aneurysectomy, CABG and aortic or aneurysectomy surgery

CABG coronary artery bypass grafting, CCI Charlson comorbidity index, COPD chronic obstructive pulmonary disease, DAH days alive and out of hospital

study quantifies this difference and shows that patient and surgical factors impact men and women differently with the latter group showing worse outcomes. The etiology of these sex-differences requires deeper examination and is likely multifactorial with differences in technical complexity, biophysiological response to perioperative stress, and patient aging [1, 2]. There may also be sex-differences in social support and caregiver networks that facilitate hospital discharge. If women take on greater care and household duties, some women may have limited access to additional social supports that can slow hospital discharge or even lead to development of new problems within their own home. Impact of physician sex on surgical outcomes was not the aim of this study but observational studies have shown difference in patient and physician sex can negatively impact outcomes particularly among female patients and male practitioners [35, 36]. Sociocultural differences between physicians and patients may impact outcomes through sex differences in communication style and decision-making but needs further evaluation using psychosocial based research methods.

DAH provides a single metric that captures important events during the recovery pathway and articulated in simple terms of days that can be calculated using common endpoints available in healthcare datasets. The difference in DAH between men and women may appear small (i.e., 1 day at DAH₃₀) but given our cohort of approximately 111,000 patients, the additional day spent in hospital by female patients (approximately 2800 days per year) has important effects on healthcare resources and bed use. DAH can be used to support patient, caregiver and physician discussions and decision making around impacts of surgery and alternative options such as less invasive percutaneous revascularization and valve procedures, medical therapy and consider combined approaches. Cardiac teams may use DAH to identify higher risk patients and those with fewer social supports to commence early discharge planning and setup of supports and services needed to aid safe hospital discharge after surgical care has been completed. DAH is a newer outcome recommended for use in perioperative care [15]. Clinicians and




Fig. 1 Forest plot showing risk adjusted effects of patient, surgical and hospital factors on days at alive and out of hospital (DAH) at 30 days

Table 3 Criterion validity of female and male patients stratified at the 10th percentile for days alive and out of hospital at 30-days assessed at 90 and 180 days

Female patients		DAH ₃₀		
		> 10th percentile	≤ 10th percentile	Total
DAH ₉₀	> 10th percentile	19,630 (97.6%)	429 (19.9%)	20,059 (90.1%)
	≤ 10th percentile	480 (2.4%)	1,731 (80.1%)	2,211 (9.9%)
	Total	20,110 (90.3%)	2,160 (9.7%)	22,270 (100)
DAH ₁₈₀	> 10th percentile	19,471 (96.8%)	586 (27.1%)	20,057 (90.1%)
	≤ 10th percentile	639 (3.2%)	1,574 (72.9%)	2,213 (9.9%)
	Total	20,110 (90.3%)	2,106 (9.7%)	22,270 (100%)
Male patients		DAH ₃₀		
		> 10th percentile	≤ 10th percentile	Total
DAH ₉₀	> 10th percentile	57,385 (98.3%)	1,234 (19.6%)	58,619 (90.6%)
	≤ 10th percentile	1,017 (1.7%)	5,073 (80.4%)	6,090 (9.4%)
	Total	58,402 (90.3%)	6,307 (9.8%)	64,709 (100)
DAH ₁₈₀	> 10th percentile	56,783 (97.2%)	1,508 (23.9%)	58,291 (90.1%)
	≤ 10th percentile	1,619 (2.8%)	4,799 (76.1%)	6,418 (9.9%)
	Total	58,402 (90.3%)	6,307 (9.8%)	64,709 (100%)

investigators can use DAH to study the effect of introducing new therapies, and of longitudinal and cross-sectional examination of patient outcomes between hospitals and within institutions as part of quality

initiative programs. Healthcare leaders and policy makers can use DAH to examine the population-level effect of new quality care initiatives to improve healthcare processes, health policies and resource planning.

The strengths of this study include a dataset of patients over 10-years in the province of Ontario where cardiac surgical care is regionalized to 11 hospitals. This study has several limitations. This includes residual confounding from e.g., absence of physiological variables in health administrative data that may identify sicker patients. However, other variables (e.g., acuity, need for preoperative ICU level care) may provide similar information. In addition, the datasets do not capture local hospital protocols and policies for managing cardiac surgical patients. However, many aspects of cardiac care that impact patient outcomes are consistent across Canadian centres such as blood conservation techniques (e.g., use anti-fibrinolytics, cell salvage), antibiotic prophylaxis, routine advanced monitoring, ICU care after surgery, and senior physician led care. Administrative data may underestimate the true incidence and severity of complications after surgery, which may have even larger effects on DAH for men and women.

In conclusion, this study shows DAH is a useful measurement tool showing appropriate change to patient and surgical factors. There are marked sex-differences in patient outcomes and DAH should be reported separately. Further research would be valuable to understand why sex-disparities exist and what new structures and care pathways are needed to narrow this gap.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12872-024-03862-7>.

Additional file 1: Figure S1. Calculating days alive and out of hospital at 30-days (DAH30) **Figure S2.** Forest plot showing risk adjusted effects of patient, surgical and hospital factors on days at alive and out of hospital (DAH) at (A) 90 days and (B) 180 days for female and male patients. **Table S1.** Cardiac surgery procedure codes. **Table S2.** Descriptive characteristics of cardiac surgery patients stratified by sex and surgical group. **Table S3.** Risk adjusted analysis of days alive and out of hospital for 30-, 90- and 180-days after removal of complications. **Table S4.** Summary of analyses with interaction variable. **Table S5.** Characteristics of male and female patients above and below the 10th percentile. **Table S6.** Days alive and out of hospital at 30 and 90 days for subtypes of isolated non-CABG and combined surgery stratified by patient sex. **Table S7.** Risk adjusted effects of patient, surgical and hospital factors on days at alive and out of hospital (DAH) at 30-days for women and men undergoing A) single non-CABG and B) combined surgical procedures.

Acknowledgements

Acknowledgements: Lu Han at ICES who assisted developing the study cohort.

Authors' contributions

AJ and D.K conceived study idea, wrote manuscript and obtained funding. V.R, T.Y and S.F supported developed of study concept. PA supported analysis. All authors have reviewed and edited the manuscript.

Funding

Angela Jerath is supported by a Merit Award, Department of Anesthesiology and Pain Medicine, and Women's Heart and Brain Award, Health Canada and

Heart and Stroke Foundation of Canada. Duminda Wijeyesundera is supported by a Merit Award from the Department of Anesthesiology and Pain Medicine at the University of Toronto, and by the Endowed Chair in Translational Anesthesiology Research at St. Michael's Hospital and the University of Toronto. Dennis Ko is supported by the Jack Tu Research Chair in Cardiovascular Outcomes Research, Sunnybrook Health Sciences Centre and University of Toronto.

Availability of data and materials

The data used in this manuscript is available at ICES, Toronto, ON, Canada. Enquiries to access and secondary use of the data should be made to the corresponding author and ICES and governed by ICES. The use of data in this project was authorized under section 45 of Ontario's Personal Health Information Protection Act, which does not require review by a research ethics board.

Declarations

Ethics approval and consent to participate

Informed consent was not required from participants. The Institute for Clinical Evaluative Sciences (ICES) is a prescribed entity under section 45 of *Ontario's Personal Health Information Protection Act* (PHIPA). Section 45 is the provision that enables analysis and compilation of statistical information related to the management, evaluation and monitoring of, allocation of resources to, and planning for the health system. Section 45 authorizes health information custodians to disclose personal health information to a prescribed entity, like ICES, without consent for such purposes. Projects conducted wholly under Sect. 45, by definition, do not require review by a Research Ethics Board. This is confirmed by research ethics board approval from Sunnybrook Health Sciences Centre. For further details on Sect. 45, please see <https://www.ipc.on.ca/wp-content/uploads/2017/07/ent-ices.pdf>.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Author details

¹Department of Anesthesia, Sunnybrook Health Sciences Center, Toronto, ON, Canada. ²Department of Anesthesiology and Pain Medicine, University of Toronto, Toronto, ON, Canada. ³ICES, 2075 Bayview Avenue, Toronto, ON, Canada. ⁴Schulich Heart Centre, Sunnybrook Research Institute, Sunnybrook Health Sciences Center, Toronto, ON, Canada. ⁵Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada. ⁶Division of Urology, Department of Surgery, Mount Sinai Hospital, Toronto, ON, Canada. ⁷Department of Surgical Oncology, University Health Network, Toronto, ON, Canada. ⁸Division of Cardiovascular Surgery, Sunnybrook Health Sciences Center, Toronto, ON, Canada. ⁹Division of Cardiovascular Surgery, Toronto General Hospital-University Health Network, Toronto, ON, Canada. ¹⁰Toronto General Hospital Research Institute, Toronto, ON, Canada. ¹¹Division of Cardiovascular Surgery, University of Toronto, Toronto, ON, Canada. ¹²Mayo Clinic Alix School of Medicine, Mayo Clinic, Rochester, MN, USA. ¹³Division of Cardiology, Toronto General Hospital-University Health Network, Toronto, ON, Canada. ¹⁴Centre for Health Services and Policy Research, University of British Columbia, Vancouver, BC, Canada. ¹⁵Department of Anesthesia, St. Michael's Hospital, Toronto, ON, Canada.

Received: 10 January 2024 Accepted: 26 March 2024

Published online: 20 April 2024

References

- Koch CG, Nussmeier NA. Gender and cardiac surgery. *Anesthesiol Clin North America*. 2003;21:675–89.
- Saxena A, Dinh D, Smith JA, Shardey G, Reid CM, Newcomb AE. Sex differences in outcomes following isolated coronary artery bypass graft surgery in Australian patients: analysis of the Australasian Society of Cardiac and Thoracic Surgeons cardiac surgery database. *Eur J Cardiothorac Surg*. 2012;41:755–62.

3. Johnston A, Mesana TG, Lee DS, Eddeen AB, Sun LY. Sex Differences in Long-Term Survival After Major Cardiac Surgery: A Population-Based Cohort Study. *J Am Heart Assoc*. 2019;8: e013260.
4. Henderson T, Shephard J, Sundararajan V. Quality of diagnosis and procedure coding in ICD-10 administrative data. *Med Care*. 2006;44:1011–9.
5. Ahmed EO, Butler R, Novick RJ. Failure-to-Rescue Rate as a Measure of Quality of Care in a Cardiac Surgery Recovery Unit: A Five-Year Study. *Ann Thorac Surg*. 2014;97:147–52.
6. Reddy HG, Shih T, Englesbe MJ, Shannon FL, Theurer PF, Herbert MA, Paone G, Bell GF, Prager RL. Analyzing “failure to rescue”: Is this an opportunity for outcome improvement in cardiac surgery? *Ann Thorac Surg*. 2013;95:1976–81.
7. Pesonen E, Vlasov H, Suojaranta R, Hippiala S, Schramko A, Wilkman E, Eranen T, Arvonen K, Mazanikov M, Salminen US, Meinberg M, Vahasilta T, Petaja L, Raivio P, Juvonen T, Pettila V. Effect of 4% Albumin Solution vs Ringer Acetate on Major Adverse Events in Patients Undergoing Cardiac Surgery With Cardiopulmonary Bypass: A Randomized Clinical Trial. *JAMA*. 2022;328:251–8.
8. Buth KJ, Gainer RA, Legare JF, Hirsch GM. The changing face of cardiac surgery: practice patterns and outcomes 2001–2010. *Can J Cardiol*. 2014;30:224–30.
9. Anzai I, Pearsall C, Blitzer D, Adeniyi A, Ning Y, Zhao Y, Argenziano M, Shimada Y, Yamabe T, Kurlansky P, George I, Smith C, Takayama H. Influence of preoperative and intraoperative factors on recovery after aortic root surgery. *Gen Thorac Cardiovasc Surg*. 2024;72:104–11.
10. Yamabe T, Zhao Y, Sanchez J, Kelebeyev S, Bethancourt CR, McMullen HL, Kurlansky PA, George I, Smith CR, Takayama H. Probability of Uneventful Recovery After Elective Aortic Root Replacement for Aortic Aneurysm. *Ann Thorac Surg*. 2020;110:1485–93.
11. Jerath A, Austin PC, Wijeyesundera DN. Days alive and out of hospital: validation of a patient-centered outcome for perioperative medicine. *Anesthesiology*. 2019;131:84–93.
12. Myles PS, Shulman MA, Heritier S, Wallace S, McLroy DR, McCluskey S, Sillar I, Forbes A. Validation of days at home as an outcome measure after surgery: a prospective cohort study in Australia. *BMJ Open*. 2017;7: e015828.
13. Fanaroff AC, Cyr D, Neely ML, Bakal J, White HD, Armstrong PW, Lopes RD, Ohman EM, Roe MT. Days alive and out of hospital: exploring a patient-centered, pragmatic outcome in a clinical trial of patients with acute coronary syndromes. *Circ Cardiovasc Qual Outcomes*. 2018;11: e004755.
14. Ariti CA, Cleland JG, Pocock SJ, Pfeffer MA, Swedberg K, Granger CB, McMurray JJ, Michelson EL, Ostergren J, Yusuf S. Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. *Am Heart J*. 2011;162:900–6.
15. Moonesinghe SR, Jackson AIR, Boney O, Stevenson N, Chan MTV, Cook TM, Lane-Fall M, Kalkman C, Neuman MD, Nilsson U, Shulman M, Myles PS. Standardised Endpoints in Perioperative Medicine—Core Outcome Measures in P, Anaesthetic Care G: Systematic review and consensus definitions for the Standardised Endpoints in Perioperative Medicine initiative: patient-centred outcomes. *Br J Anaesth*. 2019;123:664–70.
16. Wasywich CA, Gamble GD, Whalley GA, Doughty RN. Understanding changing patterns of survival and hospitalization for heart failure over two decades in New Zealand: utility of “days alive and out of hospital” from epidemiological data. *Eur J Heart Fail*. 2010;12:462–8.
17. Groff AC, Colla CH, Lee TH. Days Spent at Home — A Patient-Centered Goal and Outcome. *N Engl J Med*. 2016;375:1610–2.
18. Jerath A, Austin PC, Ko DT, Wijeyesundera HC, Fremes S, McCormack D, Wijeyesundera DN. Socioeconomic Status and Days Alive and Out of Hospital after Major Elective Noncardiac Surgery: A Population-based Cohort Study. *Anesthesiology*. 2020;132:713–22.
19. Jerath A, Laupacis A, Austin PC, Wunsch H, Wijeyesundera DN. Intensive care utilization following major noncardiac surgical procedures in Ontario, Canada: a population-based study. *Intensive Care Med*. 2018;44:1427–35.
20. Juurlink D, Preyra C, Croxford R, Chong A, Austin P. Canadian Institute for Health Information Discharge Abstract Database: A validation study. ICES investigative report. Toronto, Canada. 2006, pp 1–77.
21. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. *Diabetes Care*. 2002;25:512–6.
22. Tu K, Campbell NRC, Chen Z, Cauch-Dudek KJ, McAlister FA. Accuracy of administrative databases in identifying patients with hypertension. *Open Medicine*. 2007;1:E18–26.
23. Tu K, Chen Z, Lipscombe LL. Prevalence and incidence of hypertension from 1995 to 2005: a population-based study. *CMAJ*. 2008;178:1429–35.
24. Gershon AS, Wang C, Guan J, Vasilevska-Ristovska J, Cicuto L, To T. Identifying individuals with physician diagnosed COPD in health administrative databases. *COPD*. 2009;6:388–94.
25. K/DOQI clinical practice guidelines for chronic kidney disease. evaluation, classification, and stratification. *Am J Kidney Dis*. 2002;39:S1–266.
26. Gilbert T, Neuburger J, Kraindler J, Keeble E, Smith P, Ariti C, Arora S, Street A, Parker S, Roberts HC, Bardsley M, Vauthey JN, Dindo D, Schulick RD, de Santibanes E, Pekolj J, Slankamenac K, Bassi C, Graf R, Vonlanthen R, Padbury R, Cameron JL, Makuuchi M. The Clavien-Dindo classification of surgical complications: five-year experience. *Ann Surg*. 2009;250:187–96.
27. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg*. 2004;240:205–13.
28. Austin PC, Tu JV, Daly PA, Alter DA. The use of quantile regression in health care research: a case study examining gender differences in the timeliness of thrombolytic therapy. *Stat Med*. 2005;24:791–816.
29. Geraci M, Bottai M. Linear quantile mixed models. *Stat Comput*. 2014;24:461–79.
30. Geraci M. Linear quantile mixed models: The lqmm package for laplace quantile regression. *J Stat Softw*. 2014;57:1–29.
31. Sobol JB, Wunsch H. Triage of high-risk surgical patients for intensive care. *Critical Care*. 2011;15:217.
32. Jerath A, Sutherland J, Austin PC, Ko DT, Wijeyesundera HC, Fremes S, Karanicolos P, McCormack D, Wijeyesundera DN. Delayed discharge after major surgical procedures in Ontario, Canada: a population-based cohort study. *CMAJ*. 2020;192:E1440–52.
33. Greenwood BN, Carnahan S, Huang L. Patient-physician gender concordance and increased mortality among female heart attack patients. *Proc Natl Acad Sci U S A*. 2018;115:8569–74.
34. Wallis CJD, Jerath A, Coburn N, Klaassen Z, Luckenbaugh AN, Magee DE, Hird AE, Armstrong K, Ravi B, Esnaola NF, Guzman JCA, Bass B, Detsky AS, Satkunasivam R. Association of Surgeon-Patient Sex Concordance With Postoperative Outcomes. *JAMA Surg*. 2022;157:146–56.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.